Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling.

Clinical cancer research : an official journal of the American Association for Cancer Research·2018

Same author

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.

Therapeutic advances in medical oncology·2018

Same author

Stress effects on FosB and interleukin-8 (<i>IL8</i>)-driven ovarian cancer growth and metastasis.

The Journal of biological chemistry·2018

Same author

Stress, inflammation, and eicosanoids: an emerging perspective.

Cancer metastasis reviews·2018

Same author

Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer.

Cancer·2018

Same author

Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.

Drug delivery·2018

Search research articles

Related Experiment Video

Updated: Dec 30, 2025

Transplantation Into the Mouse Ovarian Fat Pad

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

Evolving population-based statistics for rare epithelial ovarian cancers.

Koji Matsuo¹, Hiroko Machida², Shinya Matsuzaki³

¹Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.

Gynecologic Oncology

|January 20, 2020

Summary

Rare ovarian cancers like clear cell (OCCC) and mucinous (MOC) show similar survival to high-grade serous ovarian cancer (HGSOC) in early stages. However, advanced OCCC and MOC have poorer survival, necessitating new treatment research.

Keywords:

Clear cell Low-grade serous Mucinous Ovarian cancer Rare tumor Survival

More Related Videos

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Published on: August 28, 2012

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Related Experiment Videos

Last Updated: Dec 30, 2025

Transplantation Into the Mouse Ovarian Fat Pad

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Published on: August 28, 2012

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Area of Science:

Oncology
Epidemiology
Gynecologic Oncology

Background:

Epithelial ovarian cancers (EOCs) are a heterogeneous group of malignancies.
Rare EOC subtypes, including clear cell (OCCC), mucinous (MOC), and low-grade serous (LGSOC), represent a small fraction of all ovarian cancers.
Understanding the population-based survival trends for these rare subtypes compared to the predominant high-grade serous ovarian cancer (HGSOC) is crucial for clinical management and research.

Purpose of the Study:

To describe the evolving population-based statistics for rare epithelial ovarian cancers.
To compare the overall survival (OS) of OCCC, MOC, and LGSOC to HGSOC using a large national database.
To analyze survival differences based on disease stage and over time.

Main Methods:

Retrospective observational study utilizing the Surveillance, Epidemiology, and End Results (SEER) Program database (1988-2016).
Propensity score matching was employed to compare overall survival (OS) between OCCC, MOC, LGSOC, and HGSOC.
Analysis included over 113,000 ovarian malignancies, focusing on stage-specific survival and trends in 5-year OS rates.

Main Results:

OCCC and MOC were more frequently diagnosed at early-stage disease compared to HGSOC.
For early-stage disease, OCCC and MOC showed similar OS to HGSOC, while LGSOC had superior OS.
For advanced-stage disease, OCCC and MOC exhibited poorer OS than HGSOC, whereas LGSOC had superior OS. Notably, 5-year OS rates for advanced OCCC and MOC remained unchanged over time, unlike HGSOC and LGSOC.

Conclusions:

OCCC, MOC, and LGSOC are distinct rare EOC subtypes with varying survival profiles compared to HGSOC.
While early-stage rare EOCs have a favorable to comparable prognosis, advanced-stage OCCC and MOC demonstrate disproportionately poor survival.
The lack of improvement in long-term survival for advanced OCCC and MOC underscores the urgent need for novel therapeutic strategies and further research.